Novartis reported 10.28B in Operating Expenses for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Alcon AG ALC:SW 1.78B 18M
Amgen AMGN:US $ 3.77B 854M
Bayer BAYN:GR 9.25B 765M
Biogen BIIB:US $ 2289.3M 569.2M
Bristol Myers Squibb BMY:US $ 9.99B 666M
Eli Lilly And LLY:US $ 5650.3M 202.4M
Fresenius FRE:GR 7.98B 302M
Fresenius Medical Care FME:GR 3.74B 202.58M
Galapagos GLPG:NA 174.96M 2.19M
Genmab GEN:DC 1.05B 108M
Gilead Sciences GILD:US $ 3533M 1237M
GlaxoSmithKline GSK:LN 6.42B 692M
GRIFOLS GRF:SM 971.78M 85.9M
H. Lundbeck A/S LUN:DC 3.39B 680M
Hikma Pharmaceutical HIK:LN 900M 61M
Johnson & Johnson JNJ:US $ 16.65B 1.76B
Lonza Group LONN:SW 2.22B 1.07B
Merck MRK:GR 3.59B 399M
Merk MRK:US $ 9066M 5698M
Novartis NOVN:VX 10.28B 107M
Novartis NVS:US 9.82B 464M
Orion ORNBV:FH 183.9M 9.8M
Pfizer PFE:US $ 13063M 3998M
Philips PHIA:NA € 3879M 1328M
Recordati REC:IM 259.95M 9.88M
Regeneron Pharmaceuticals REGN:US $ 1416M 160.1M